BACKGROUND: Chlamydia trachomatis infection is highly prevalent among young women in the United States. Prevention of long-term sequelae of infection, including tubal factor infertility, is a primary goal of chlamydia screening and treatment activities. However, the population-attributable fraction of tubal factor infertility associated with chlamydia is unclear, and optimal measures for assessing tubal factor infertility and prior chlamydia in epidemiological studies have not been established. Black women have increased rates of chlamydia and tubal factor infertility compared with White women but have been underrepresented in prior studies of the association of chlamydia and tubal factor infertility. OBJECTIVES: The objectives of the study were to estimate the population-attributable fraction of tubal factor infertility associated with Chlamydia trachomatis infection by race (Black, non-Black) and assess how different definitions of Chlamydia trachomatis seropositivity and tubal factor infertility affect population-attributable fraction estimates. STUDY DESIGN: We conducted a case-control study, enrolling infertile women attending infertility practices in Birmingham, AL, and Pittsburgh, PA, during October 2012 through June 2015. Tubal factor infertility case status was primarily defined by unilateral or bilateral fallopian tube occlusion (cases) or bilateral fallopian tube patency (controls) on hysterosalpingogram. Alternate tubal factor infertility definitions incorporated history suggestive of tubal damage or were based on laparoscopic evidence of tubal damage. We aimed to enroll all eligible women, with an expected ratio of 1 and 3 controls per case for Black and non-Black women, respectively. We assessed Chlamydia trachomatis seropositivity with a commercial assay and a more sensitive research assay; our primary measure of seropositivity was defined as positivity on either assay. We estimated Chlamydia trachomatis seropositivity and calculated Chlamydia
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I nfertility affects millions of people in the United States, 1 with tubal factor infertility (TFI) contributing to a substantial proportion of these cases. 2 Sexually transmitted infections such as Chlamydia trachomatis infection (chlamydia), which is highly prevalent among young women in the United States, 3 are a primary risk factor for TFI. While frequently asymptomatic, chlamydia can ascend to the upper genital tract, causing acute or subclinical pelvic inflammatory disease (PID), fallopian tube damage, and increased risk for ectopic pregnancy and TFI. 4, 5 Prevention of these sequelae is a primary goal of chlamydia screening and treatment activities. However, the population-attributable fraction (PAF) 6 of TFI associated with chlamydia, which provides a measure of TFI burden that might be prevented by eliminating chlamydial infection, is unclear. Furthermore, optimal measures for assessing TFI and prior chlamydia in epidemiological studies have not been established. Black women have increased rates of chlamydia 3, 7 and TFI 8, 9 compared with White women but have been underrepresented in prior studies of the association of chlamydia and TFI. An estimate of the PAF of TFI associated with chlamydia would inform evaluation of chlamydia prevention efforts.
The primary objective of this casecontrol study was to estimate the PAF of TFI associated with chlamydia by race among infertile women assessed for fallopian tube patency. Secondary objectives were as follows: (1) determine C trachomatis seropositivity rates in infertile women using a commercial assay and a newer, more sensitive research assay, (2) calculate the odds of C trachomatis seropositivity in infertile women with obstructed vs patent fallopian tubes (TFI vs non-TFI, respectively), and (3) assess how estimates of odds ratio (OR) and PAF are affected by different definitions of C trachomatis seropositivity and TFI.
Materials and Methods
Between October 2012 and June 2015, women were recruited from a private, community-based infertility practice in Birmingham, AL, and a universityaffiliated infertility practice in Pittsburgh, PA. Eligibility criteria included age 19e42 years, infertility (inability to achieve an intrauterine pregnancy after 12 months of regular sexual intercourse without contraception), having a hysterosalpingogram (HSG) within 12 months of enrollment, ability to provide informed consent, and a current US mailing address.
Eligible women were referred to the study by clinical staff in Pittsburgh and identified directly by clinician investigators in Birmingham. We aimed to enroll all eligible women, with an expected ratio of 1 control per case for Black participants and 3 controls per case for non-Black participants, based on historical prevalence of TFI diagnosis among women evaluated for infertility at the enrollment sites. Information on demographic and clinical risk factors was collected by participant interview and infertility clinic record review. Serum specimens were collected for C trachomatis antibody testing.
Written informed consent was obtained from all participants. Study approval was obtained from the Institutional Review Boards of the University of Alabama at Birmingham and the University of Pittsburgh. Centers for Disease Control and Prevention (CDC) human subjects review determined that CDC investigators were not engaged in human subjects research for this study and CDC institutional review board approval was not required.
Sera were evaluated at the CDC for immunoglobulin (Ig) G antibody to the C trachomatis major outer membrane protein peptide using the commercially available C trachomatis-IgG plus Medac assay kit (catalog number 497-PLUS; Medac, Hamburg, Germany) according to the manufacturer's instructions (Medac IgG MOMP). In addition, sera were evaluated for IgG1 and IgG3 antibodies to C trachomatis elementary bodies (EBs) at the University of Alabama at Birmingham according to a previously published protocol (EB enzyme-linked immunosorbent assay [ELISA]). 10, 11 For our a priori selected primary definition of TFI (HSG case definition), participants were categorized as TFI case-patients if their enrollment HSG showed unilateral or bilateral fallopian tube blockage (as defined by lack of free spill of dye into the pelvic cavity) or as non-TFI infertile controls if their enrollment HSG showed bilateral patent fallopian tubes with no other tubal abnormalities and they had no prior history of tubal ectopic pregnancy or surgery to repair blocked tubes.
As an exploratory analysis, 2 other TFI definitions were used. First, participants who could not be categorized as casepatients according to the primary case definition but who had HSG or historical evidence suggestive of tubal damage (tubal abnormalities other than obstruction on HSG, bilateral patent tubes on HSG with prior history of tubal ectopic pregnancy or surgery to repair blocked tubes, or presence of a single patent tube on HSG with a history of contralateral tube removal because of tubal ectopic pregnancy or hydrosalpinx) were categorized as TFI casepatients using an expanded case definition.
Second, a laparoscopy case definition was used to categorize participants, independently of HSG results, as TFI case-patients if they had a laparoscopy with evidence of tubal damage (tubal occlusion or fibrosis, fragmented fimbriae, hydrosalpinx, peritubal adhesions) or as non-TFI infertile controls if they had a laparoscopy within 1 year of study enrollment with no evidence of tubal damage.
Our a priori selected primary measure of C trachomatis seropositivity was defined as seropositivity by either Medac IgG MOMP or EB ELISA (IgG1 or IgG3). To explore the impact of substituting different C trachomatis seropositivity definitions on study findings, C trachomatis seropositivity was alternatively defined in 5 Analyses were performed stratified by race (Black, non-Black). The target sample size of 784 (118 Black and 666 non-Black) was determined based on a range of values for C trachomatis seroprevalence among infertile women with and without TFI reported in the literature 12 along with the anticipated number of eligible participants identified during the enrollment period. Based on C trachomatis seroprevalence measured among the first 300 enrolled participants (70% of Black controls and 12% of nonBlack controls were seropositive by EB ELISA), we anticipated achieving 80% power to detect a significant (2-sided alpha ¼ 0.05) association between C trachomatis seropositivity and TFI, assuming an odds ratio of at least 3 among Blacks and at least 2 among nonBlacks. c 2 , Fisher exact, Cochran-MantelHaenszel, and Wilcoxon MannWhitney tests were used to compare characteristics of cases and controls. C trachomatis seropositivity with 95% confidence intervals (CIs) was calculated under the binomial distribution. We used logistic regression to assess the relationships between exposure variables and TFI. Age, age at first vaginal sex, and the lifetime number of male sex partners were categorized as less than or equal to vs greater than the median value, and ajog.org GYNECOLOGY Original Research household income was categorized using predefined categories included on the questionnaire.
Multivariable analyses were performed using the primary TFI case definition and C trachomatis seropositivity definition and adjusted for study site, participant age, household income, and other variables associated with TFI at P < .1 in a bivariate analysis. Associations with P < .05 were considered statistically significant. Crude and adjusted PAFs and 95% CIs (stratified by race) were calculated based on methods described by Bruzzi et al 13 and Efron and Tibshirani. 14 We examined the impact of substituting different C trachomatis seropositivity and TFI case definitions on estimated crude ORs and PAFs. Statistical analyses were performed using SAS (version 9.3, SAS Institute, Cary, NC).
Results
The Figure illustrates enrollment and inclusion in analyses. All eligible women approached were enrolled in the study. Of 784 patients enrolled, 13 were excluded because they did not meet inclusion criteria (n ¼ 6) or could not be categorized by any of the case definitions (n ¼ 7). Of the remaining 771 patients, 44 had a history or HSG findings suggestive of TFI but could not be categorized using the HSG case definition; these participants were included as cases in the analyses using the expanded case definition. Laparoscopy was performed within the designated time frame among 169 participants.
Characteristics of the 727 study participants (107 Black and 620 nonBlack) categorized according to the HSG case definition are presented in Table 1 . Participants ranged in age from 19 through 42 years. Participants of non-Black race were predominantly White (96%). Case-patients were significantly more likely than controls to report household income <$50,000 and a history of chlamydia, trichomoniasis, PID, surgically confirmed endometriosis, and prior abdominal or pelvic surgery but significantly less likely to report a history of combined hormonal contraceptive use. Casepatients had a significantly longer median duration of infertility than controls (28 vs 23 months).
Characteristics of the 771 participants included in the expanded case definition analysis were similar to those included in the HSG case definition analysis (Appendix Table 1 ). Characteristics of the 169 participants categorized according to the laparoscopy case definition are presented in Appendix Table 2 . Distribution of cases and controls contributed by the 2 sites differed for the laparoscopy case definition, with the Birmingham site contributing 56% of cases and 77% of controls.
C trachomatis seropositivity by race, case status, and serological measure used is presented in Table 2 for the 727 participants categorized according to the HSG case definition. Using the primary definition of C trachomatis seropositivity, 81% (95% CI, 73e89%) of Black and 31% (95% CI, 28e35%) of non-Black participants were seropositive (P < .001). Using different definitions of C trachomatis seropositivity, point estimates of seropositivity were consistently higher among case-patients vs controls for Excluded due to: incomplete data (n=2), failure to meet study inclusion criteria (n=6), equivocal HSG findings (n=2), or single patent tube with contralateral tube removed for reasons other than tubal ectopic pregnancy or hydrosalpinx (n=3)
Included as cases in expanded case defini on but could not be categorized using HSG (primary) case defini on due to: BPT with other tubal abnormali es on HSG (n=18), BPT with prior history of tubal ectopic pregnancy (n=13), single patent tube with prior removal of contralateral tube due to ectopic pregnancy or hydrosalpinx (n=11), or BPT with prior history of surgery to repair blocked tubes (n=5) 1 No laparoscopy performed during designated me frame (n=558)
Flow chart of study enrollment and inclusion in analyses using 3 TFI case definitions.
BPT, bilateral patent tubes; HSG, hysterosalpingogram; TFI, tubal factor infertility.
Gorwitz et al. PAF of TFI associated with chlamydia. Am J Obstet Gynecol 2017.
Original Research GYNECOLOGY ajog.org Crude ORs and 95% CIs for associations between C trachomatis seropositivity and TFI by race, TFI case definition, and chlamydia serological measure are presented in Table 3 . Using the primary definitions for TFI and seropositivity, ORs were less than 1.5, and no significant association was detected. Among Blacks, no significant association was detected, regardless of case definition used; however, the magnitude of association was greatest using the laparoscopy case definition.
Among non-Blacks, a significant association was consistently detected using the expanded case definition, and the magnitude of association was increased using the laparoscopy case definition. Definition of C trachomatis seropositivity also had an impact on the findings, with a significant association detected consistently when defining seropositivity based on EB ELISA (IgG1 or IgG3 response), EB ELISA IgG3, or a positive response on both EB ELISA and Medac IgG MOMP. Table 4 presents ORs and 95% CIs for bivariate associations between measured covariates and TFI and multivariable associations between C trachomatis seropositivity and TFI, adjusting for these covariates. Among Black participants, a history of illicit drug use, income, and a history of combined hormonal contraception were independently associated with TFI, with the latter 2 being protective associations. Among non-Blacks, history of trichomoniasis, surgically confirmed endometriosis, and income were independently associated with TFI, with income being a protective association. No significant association between C trachomatis seropositivity and TFI was detected in the multivariable models for either Blacks or non-Blacks, although Table 3 ).
Comment
In this study, designed to estimate the PAF of TFI associated with chlamydia, we found that race, C trachomatis serological measure, and TFI case definition had a substantial impact on our findings. Because of a limited number of Black participants, our PAF estimates for Blacks were imprecise, with an estimate of 15% (95% CI, e7% to 68%) based on primary measures of seropositivity and TFI. Among non-Blacks, estimated PAF was 11% (95% CI, e3% to 23%) using the primary seropositivity measure and case definition; however, substitution of alternative measures resulted in PAF estimates as high as 26% (95% CI, 10e40%).
High C trachomatis seroprevalence among infertile women with patent tubes, which was most striking among Black participants (80%), might have obscured an association between chlamydia and TFI and resulted in a PAF that underestimates the true etiological role of chlamydia in TFI.
High C trachomatis seropositivity in infertile Black women, regardless of tubal patency, likely reflects high 
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infection rates among Black women in the communities served by our study sites. This is consistent with US national data on the distribution of chlamydia by race. 3, 7 High seropositivity in Black controls might represent a high background prevalence of uncomplicated lower genital tract chlamydia, unrelated to infertility, or could indicate the presence of chlamydia-associated nonocclusive (functional) fallopian tube damage. We selected controls from among infertile women attending the same clinics as the TFI cases to increase comparability and minimize bias from unmeasured confounders; however, determination of C trachomatis seropositivity in fertile controls drawn from the same population would be helpful to assess which of these explanations is most accurate.
Lower C trachomatis seroprevalence in non-Black case-patients, with PAF point estimates ranging from 8% to 26%, suggests that, although chlamydia likely plays a role in TFI in this population, other infectious or noninfectious sources of TFI are also prevalent. It is possible that chlamydia screening programs have resulted in decreased rates of chlamydia-associated PID in this population or that early effective management of PID has resulted in decreased progression to TFI. This hypothesis is supported by the declining rates of PID diagnoses 7 and the declining prevalence of TFI diagnosis among women using assisted reproductive technology 15 in the United States, reported for all races combined. In addition, in a 2002 report, C trachomatis was identified in the cervix or endometrium of less than one quarter of women with acute PID. 16 The fact that C trachomatis seropositivity was substantially more common than a reported or documented history of chlamydia underscores the need for a biomarker of prior chlamydia. Among 9 studies published during 2000e2015 that assessed C trachomatis seropositivity as a marker of prior chlamydia in TFI cases and infertile controls using IgG MOMP assays, seropositivity ranged from 23% to 74% among cases and 9% to 33% among controls. The results we obtained using the Medac IgG MOMP assay were within this range, except that IgG MOMP seropositivity was lower in our non-Black case-patients (22% [15%, 29%]) and higher in our Black controls (48% [35%, 62%]). None of these studies presented PAF of TFI because of chlamydia, none were performed in the United States or a location with chlamydia screening recommendations in place, and all were either restricted to White participants or did not present participant race. Furthermore, in contrast to previous studies, we added a newer EB ELISA demonstrated to detect C trachomatis seropositivity in 90% of individuals with current genital chlamydia, compared with 73% detected with the Medac IgG MOMP assay. 10 Not surprisingly, seropositivity was higher when based on the more sensitive EB ELISA, particularly in Black participants. The magnitude of the EB ELISA response has been shown to differ by race, with stronger responses detected in Black vs White persons with current genital chlamydia or unknown infection status. 10 Because the magnitude of antibody response (especially IgG3) may decline over time following resolution of infection, the ability of this assay to detect seropositivity in persons with a more remote history of infection may be greater in Blacks. More frequent reexposure and repeat infection among Black women could also contribute to a more sustained antibody response.
17-25
A notable strength of our study was the use of a C trachomatis serological assay with improved sensitivity compared with assays used in previously published studies. In addition, our study provides new insights into the association between chlamydia and infertility in an era when chlamydia screening and treatment recommendations have been implemented, and attempts to assess the impact of race on this association, providing important data that will inform future studies.
Our study also had limitations. Although we aimed to enroll all eligible women, some might have been missed. Our results might not be generalizable to all infertile women. We lacked the Original Research GYNECOLOGY ajog.org statistical power to detect the hypothesized effect size among Blacks. We lacked biomarkers to evaluate the contribution of other infections to TFI. Finally, laparoscopy, which is considered the reference standard for diagnosing TFI, was not routinely performed in all patients at our study sites; therefore, HSG was used for primary assessment of tubal occlusion.
A recent meta-analysis of 7 studies 26 found that HSG had an overall 53% sensitivity and 87% specificity compared with laparoscopy for detecting unilateral tubal occlusion. Low sensitivity of HSG in detecting tubal occlusion might have resulted in misclassification of some cases as controls and biased our results toward the null. When we included as cases women with bilateral patent tubes but other tubal abnormalities on HSG or with historical evidence of tubal damage (ie, the expanded case definition), we consistently detected a significant association between chlamydia and TFI among non-Blacks. However, the authors of the previously mentioned metaanalysis reported that HSG sensitivity compared with laparoscopy was significantly lower in women without as compared to with risk factors for tubal pathology (eg, history of PID), suggesting that laparoscopy is not a perfect reference standard. Furthermore, neither HSG nor laparoscopy can reliably detect functional damage in patent tubes, highlighting the need for more reliable, noninvasive markers of tubal damage.
In addition to our primary outcome, key findings of our study include an extraordinarily high C trachomatis seroprevalence among infertile Black controls and variability in magnitude and statistical significance of OR and PAF estimates based on choice of C trachomatis seropositivity measure and TFI case definition. Improved understanding of immune responses to chlamydia in this population and additional evaluation of tests used to measure these responses may allow refinement of estimates in future studies. Attention should also be directed toward exploring the contribution of other infectious and noninfectious exposures to TFI. 
